# US 2023/0145361 A1 · Method, comprising bacteriophages, for reducing the population of at least one adipogenic bacterial species, and bacteriophages and the use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0145361 A1
- Document ID: US20230145361A1
- Status: Published application
- Kind: A1
- Application number: 17/795,327
- Filed: 2021-01-20
- Published: 2023-05-11
- Earliest claimed: 2020-01-27
- Inventors: OXANA KARPF
- Web page: https://patentgrep.com/patent/US20230145361A1

## CPC

- A01N 63/40: Viruses, e.g. bacteriophages
- C12N 15/86: Viral vectors
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2795/00032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/00043: viral genome or elements thereof as genetic vector
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for reducing the population of at least one adipogenic bacteria species, the method comprising the following steps: a) providing a biologic sample which comprises at least one adipogenic bacteria species; and b) providing bacteriophages of at least one bacteriophage species which are specific to at least one adipogenic bacteria species and comprise at least one nucleic acid functionally bound to a promoter and/or to a regulatory element; and c) exposing the biologic sample to and incubating it with the bacteriophages, incubation taking place until the population of the adiopogenic bacteria species has been reduced by at least 70%; as well as relating to bacteriophages and their use.

## Claims

### Claim 1

A method for reducing the population of at least one adipogenic bacteria species, the method comprising the following steps:
a) providing a biologic sample which comprises bacteria of at least one adipogenic bacteria species; and
b) providing bacteriophages of at least one bacteriophage species which are specific to at least one adipogenic bacteria species and which comprise at least one nucleic acid functionally bound to a promoter and/or to a regulatory element, the nucleic acid being chosen from among the group of:
i. a nucleic acid sequence which codes for at least one antibacterial nucleic acid molecule; and
ii. a nucleic acid sequence which codes a nucleic acid molecule, at least 50% of which is identical with the nucleic acid molecule coded by the nucleic acid sequences coded in i.; and
iii. a nucleic acid sequence which codes for at least one antibacterial polypeptide; and
iv. a nucleic acid sequence which codes a polypeptide, at least 50% of which is identical with a polypeptide coded by the nucleic acid sequences in iii.; and
v. a nucleic acid sequence for a fragment of a nucleic acid from i, ii, iii, iv, the fragment coding a nucleic acid molecule or a polypeptide; and
c) exposing the biologic sample to and incubating it with the bacteriophages, incubation taking place until the population of the adiopogenic bacteria species has been reduced by at least 70%.

### Claim 2 (depends on 1)

The method according to claim 1, wherein subsequently to step c), the reduction of the population of the adipogenic bacteria species is evaluated.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the nucleic acid has two or more promoters and/or regulatory elements.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the nucleic acid codes nucleic acid sequences for two or more nucleic acid molecules, polypeptides and/or fragments of the same.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the adipogenic bacteria species is anaerobic and/or aerobic and wherein the bacteria species is attributable to the strain Actinobacteria, Bacteroidetes, Firmicutes or Proteobacteria.

### Claim 6 (depends on 1)

A kit for implementing the method according to claim 1 comprising:
a) a container comprising bacteriophages of at least one bacteriophage species, which are specific to at least one adipogenic bacteria species and comprise at least one nucleic acid functionally bound to a promoter and/or a regulatory element; and
b) instructions for implementing the method.

### Claim 7

A bacteriophage comprising at least one nucleic acid functionally bound to a promoter and/or a regulatory element, the bacteriophage being specific to at least one adipogenic group of bacteria and the nucleic acid being chosen from among the group of:
a) a nucleic acid sequence which codes for at least one antibacterial nucleic acid molecule; and
b) a nucleic acid sequence which codes a nucleic acid molecule, at least 50% of which is identical with the nucleic acid molecule coded by the nucleic acid sequences from a); and
c) a nucleic acid sequence which codes for at least one antibacterial polypeptide; and
d) a nucleic acid sequence which codes a polypeptide, at least 50% of which is identical with a polypeptide coded by the nucleic acid sequence from c); and
e) a nucleic acid sequence for a fragment of a nucleic acid from a), b), c) or d), the fragment coding a nucleic acid molecule or a polypeptide.

### Claim 8 (depends on 7)

The bacteriophage according to claim 7, wherein the nucleic acid has two or more promoters and/or regulatory elements.

### Claim 9 (depends on 7)

The bacteriophage according to claim 7, wherein the nucleic acid codes nucleic acid sequences for two or more nucleic acid molecules, polypeptides and/or fragments of the same.

### Claim 10 (depends on 7)

The bacteriophage according to claim 7, wherein the adipogenic bacteria species is anaerobic and/or aerobic and wherein the bacteria species is attributable to the strain Actinobacteria, Bacteroidetes, Firmicutes or Proteobacteria.

### Claim 11 (depends on 7)

The bacteriophages according to claim 7 for use in medication to change the intestinal flora, in medication for achieving and/or maintaining weight reduction, in medication for preventing weight gain and/or in medication for treating overweight, obesity, a metabolic disorder, cardiovascular disease, a bacterial infection, a metabolic disease, metabolic syndrome and/or cancer.

### Claim 12 (depends on 7)

The bacteriophages according to claim 7 for use in treating overweight, obesity, metabolic disorder, cardiovascular disease, bacterial infection, metabolic disease, metabolic syndrome and/or cancer.

### Claim 13 (depends on 7)

The bacteriophages according to claim 7 for use in a therapeutic method or in a non-therapeutic method to change the composition of the intestinal flora, in a therapeutic method and/or in a non-therapeutic method for achieving and/or maintaining weight loss, in a therapeutic method or in a non-therapeutic method for preventing weight gain and/or in a therapeutic method and/or in a non-therapeutic method for treating overweight, obesity, metabolic disorder, cardiovascular disease, bacterial infection, metabolic disease, metabolic syndrome and/or cancer.

### Claim 14 (depends on 11)

The bacteriophages and/or pharmaceutical composition according to claim 11, wherein the bacterial infection is a bacterial infection of the airways, the teeth, the mouth, the jaw, the eye, the musculoskeletal system, the blood, the gastrointestinal tract, the skin, the cardiovascular system, the hormonal balance, the psyche, the immune system, the nervous system, the metabolism, wounds and/or the urogenital tract.

### Claim 15 (depends on 7)

A pharmaceutical composition comprising bacteriophages according to claim 7 and at least one other component for use in medication to change the intestinal flora, in medication for achieving and/or maintaining weight reduction, in medication for preventing weight gain and/or in medication for treating overweight, obesity, a metabolic disorder, cardiovascular disease, a bacterial infection, a metabolic disease, metabolic syndrome and/or cancer.

### Claim 16 (depends on 7)

A pharmaceutical composition comprising bacteriophages according to claim 7 and at least one other component for use in treating overweight, obesity, metabolic disorder, cardiovascular disease, bacterial infection, metabolic disease, metabolic syndrome and/or cancer.

### Claim 17 (depends on 7)

A pharmaceutical composition comprising bacteriophages according claim 7 and at least one other component for use in a therapeutic method or in a non-therapeutic method to change the composition of the intestinal flora, in a therapeutic method and/or in a non-therapeutic method for achieving and/or maintaining weight loss, in a therapeutic method or in a non-therapeutic method for preventing weight gain and/or in a therapeutic method and/or in a non-therapeutic method for treating overweight, obesity, metabolic disorder, cardiovascular disease, bacterial infection, metabolic disease, metabolic syndrome and/or cancer.
